How to Cite
摘要
Холангиоцеллюлярный рак является вторым по распространенности злокачественным заболеванием печени после гепатоцеллюлярного рака. В последние десятилетия были внедрены различные методы лечения в онкологии. В то же время возможности лечения больных с холангиоцеллюлярным раком остаются по-прежнему ограниченными. гемцитабин и цисплатин являются препаратами выбора в первой линии лекарственной терапии у пациентов с нерезектабельной опухолью. Вторая линия химиотерапии не стандартизирована и ее выбор зависит от выбора терапии первой линии. Анализ применения препаратов таргетной терапии показал противоречивые или отрицательные результаты. В целом, комбинированная терапия превосходит монохимиотерапию первой линии. Изучение эффективности препаратов для терапии второй линии имеет большое значение, поскольку в настоящее время не существует стандартов лекарственного лечения. не имеется достоверных данных эффективности применения адъювантной терапии совместно с хирургическим лечением. Данное обстоятельство требует проведения больших рандомизированных исследований. В то же время во многих исследованиях показана корреляция увеличения выживаемости у пациентов с плохим прогнозом при проведении адъювантной терапии. Изучение молекулярного профиля привело к более глубокому пониманию генетических изменений, лежащих в основе развития злокачественного новообразования, и, возможно, будущая дифференцировка анатомической или молекулярной структур будет оптимальной для подбора адекватной химиотерапии.
参考
Бредер В.В. Рак желчевыводящей системы // Практическая онкология. - 2012. - Т. 13. - 4(52). - С. 269-275.
Патютко Ю.И., Поляков А.Н., Котельников А.Г., и др. Хирургическое и комбинированное лечение больных с опухолью Клацкина // Хирургия. - 2014. - № 10. - С. 25-32.
Alvaro D., Crocetti E., Ferretti S., et al. Descriptive epidemiology of cholangiocarcinoma in Italy // Dig Liver Dis. - 2010. - Vol. 42(7). - P 490-495. - 10.1016/j. dld.2009.10.009. DOI: 10.1016/j.dld.2009.10.009
Andersen J.B., Spee B., Blechacz B.R., et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors // Gastroenterology. - 2012. - Vol. 142(4). - P 1021-1031. - e15. - 10.1053/j. gastro.2011.12.005. DOI: 10.1053/j.gastro.2011.12.005
Bekaii-Saab T., Phelps M.A., Li X., et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers // J. Clin. Oncol. - 2011. - Vol. 29(17). - P 2357-2363. - 10.1200/ JCO.2010.33.9473. DOI: 10.1200/JCO.2010.33.9473
Bengala C., Bertolini F., Malavasi N., et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial // Br. J. Cancer. - 2010. - Vol. 102(1). - P 68 72. - DOI: 10.1038/sj.bjc.6605458
Ben-Josef E., Guthrie K.A., El-Khoueiry A.B., et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma // J. Clin. Oncol. - 2015. - Vol. 33(24). - P 2617-2622. - doi: 10.1200ДIШ.2014.60.2219.
Brieau B., Dahan L., De Rycke Y., et al. Second-line chemotherapy for advanced biliary tract Cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Ent rologues Oncologues // Cancer. - 2015. - Vol. 121(18). - P. 3290-3297. - DOI: 10.1002/cncr.29471
Cho J.Y., Paik Y.H., Chang Y.S., et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma // Cancer. - 2005. - Vol. 104(12). - P 2753-2758.
Ducreux M., Rougier P., Fandi A., et al. Effective treatment of advanced biliary tract carcinoma using 5-fluoro-uracil continuous infusion with cisplatin // Ann Oncol. - 1998. - 9(6). - P. 653-656.
Eckel F., Brunner T., Jelic S.; ESMO Guidelines Working Group. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. - 2011. - 22(Suppl 6). - P vi40-44. - 10.1093/ annonc/mdr375. DOI: 10.1093/annonc/mdr375
El-Khoueiry A.B., Rankin C., Siegel A.B., et al. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma // Br. J. Cancer. - 2014. - Vol. 110(4). - P. 882887. - DOI: 10.1038/bjc.2013.801
El-Khoueiry A.B., Rankin C.J., Ben-Josef E., et al. SWOG 0514: a phase II study of sorafenib in patients with unre-sectable or metastatic gallbladder carcinoma and cholangiocarcinoma // Invest New Drugs. - 2012. - Vol. 30(4). - P 1646-1651. - DOI: 10.1007/s10637-011-9719-0
Farley D.R., Weaver A.L., Nagorney D.M. «Natural history» of unresected cholangiocarcinoma: patient outcome after noncurative intervention // Mayo Clin. Proc. - 1995. - №70. - P. 425-429.
Glazer E.S., Liu P., Abdalla E.K., et al. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins // J. Gastrointest. Surg. - 2012. - Vol. 16(9). - P. 16661671. - DOI: 10.1007/s11605-012-1935-1
Goyal L., Zheng H., Yurgelun M.B. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma // Cancer. - 2017. - Vol. 123(11). - P. 1979-1988. - DOI: 10.1002/cncr.30571
Graham J.S., Boyd K., Coxon F.Y., et al. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract // BMC Res Notes. - 2016. - №9. - P. 161. - DOI: 10.1186/s13104-015-1778-4
Gruenberger B., Schueller J., Heubrandtner U., et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study // Lancet Oncol. - 2010. - Vol. 11(12). - P. 1142-1148. - DOI: 10.1016/S1470-2045(10)70247-3
Halim A., Ebrahim M.A., Saleh Y. A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas // Jpn J. Clin. Oncol. - 2011. - Vol. 41(2). - P. 217-224. - DOI: 10.1093/jjco/hyq207
Hong Y.S., Lee J., Lee S.C., et al. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer // Cancer Chemother Pharmacol. - 2007. - Vol. 60(3). - P. 321-328.
Kim H.J., Lee N.S., Lee S.C., et al. A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer // Cancer Chemother Pharmacol. - 2009. - Vol. 64(2). - P. 371-377. - DOI: 10.1007/s00280-008-0883-7
Kim K.P., Jang G., Hong Y.S., et al. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity // Br. J. Cancer. - 2011. - Vol. 104(4). - P. 605-612. - DOI: 10.1038/bjc.2011.17
Kim T.W., Chang H.M., Kang H.J. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer // Ann Oncol. - 2003. - Vol. 14(7). - P. 1115-1120.
Knox J.J., Hedley D., Oza A., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial // J. Clin. Oncol. - 2005. - Vol. 23(10). - P. 2332-2338.
Lamarca A., Hubner R.A., David Ryder W., Valle J.W. Second-line chemotherapy in advanced biliary cancer: a systematic review // Ann Oncol. - 2014. - Vol. 25(12). - P. 2328-2338. - DOI: 10.1093/annonc/mdu162
Lee J., Park S.H., Chang H.M., et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study // Lancet Oncol. - 2012. - Vol. 13(2). - P. 181188. - 10.1016/S 1470-2045(11)70301-1. DOI: 10.1016/S1470-2045
Lee J.K., Capanu M., O'Reilly E.M., et al. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas // Br. J. Cancer. - 2013. - Vol. 109(4). - P. 915-919. - DOI: 10.1038/bjc.2013.432
Li H., Zhang Z.Y., Zhou Z.Q., et al. Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.// Oncotarget. - 2016. - 7(18). - P. 26888-26897. DOI: 10.18632/oncotarget.8590
McNamara M.G., Walter T., Horgan A.M., et al. Outcome of adjuvant therapy in biliary tract cancers // Am J. Clin. Oncol. - 2015. - Vol. 38(4). - P. 382-387. - DOI: 10.1097/COC.0b013e31829e19fb
Moehler M., Maderer A., Schimanski C., et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme // Eur. J. Cancer. - 2014. - Vol. 50(18). - P. 3125-3135. - 10.1016/j. ejca.2014.09.013. DOI: 10.1016/j.ejca.2014.09.013
Murakami Y., Uemura K., Sudo T., et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma // Ann Surg. Oncol. - 2011. - Vol. 18(3). - P. 651-658. - 10.1245/ s10434-010-1325-4. DOI: 10.1245/s10434-010-1325-4
Novarino A.M., Satolli M.A., Chiappino I., et al. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer // Am J. Clin. Oncol. - 2013. - Vol. 36(5). - P. 466-471. - 10.1097/œC.0b013e31825691c3. DOI: 10.1097/?C.0b013e31825691c3
Oh S.Y., Jeong C.Y., Hong S.C., et al. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness // Invest New Drugs. - 2011. - Vol. 29(5). - P.1066-1072. - DOI: 10.1007/s10637-010-9417-3
Okusaka T., Nakachi K., Fukutomi A., et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan // Br. J. Cancer. - 2010. - Vol. 103(4). - P. 469-474. - DOI: 10.1038/sj.bjc.6605779
Pant S., Saleh M., Bendell J., et al. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors // Ann Oncol. - 2014. - Vol. 25(7). - P. 14161421. - DOI: 10.1093/annonc/mdu157
Petrioli R., Roviello G., Fiaschi A.I., et al. Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer // Anticancer Drugs. - 2015. - Vol. 26(6). - P. 682-686. - DOI: 10.1097/CAD.0000000000000233
Plentz R.R., Malek N.P. Systemic Therapy of Cholangio-carcinoma // Visc Med. - 2016. - 32(6). - P. 427430. - DOI: 10.1159/000453084
Santoro A., Gebbia V., Pressiani T., et al. A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study // Ann Oncol. - 2015. - Vol. 26(3). - P. 542-547. - DOI: 10.1093/an-nonc/mdu576
Sasaki T., Isayama H., Nakai Y., et al. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer // Cancer Chemother Pharmacol. - 2013. - Vol. 71(4). - P. 973-979. - DOI: 10.1007/s00280-013-2090-4
Sasaki T., Isayama H., Nakai Y., et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine // Invest New Drugs. - 2012. - Vol. 30(2). - P. 708713. - DOI: 10.1007/s10637-010-9553-9
Shaib Y.H., Davila J.A., McGlynn K., El-Serag H.B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? // J. Hepatol. - 2004. - Vol. 40(3). - P. 472-477.
Suzuki E., Ikeda M., Okusaka T., et al. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer // Cancer Chemother Pharmacol. - 2013. - Vol. 71(5). - P. 1141-1146. - DOI: 10.1007/s00280-013-2106-0
Taïeb J., Mitry E., Boige V., et al. Optimization of 5-fluo-rouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma // Ann Oncol. - 2002. - Vol. 13(8). - P. 1192-1196.
Valle J.W., Wasan H., Johnson P., et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study -The UK ABC-01 Study // Br. J. Cancer. - 2009. - Vol. 101(4). - P. 621-627. - DOI: 10.1038/sj.bjc.6605211
Valle J.W., Wasan H., Lopes A., et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial // Lancet Oncol. -2015. - Vol. 16(8). - P. 967-978. - 10.1016/ S1470-2045(15)00139-4. DOI: 10.1016/S1470-2045
Voss J.S., Holtegaard L.M., Kerr S.E., et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions // Hum Pathol. - 2013. - Vol. 44(7). - P. 1216-1222. - 10.1016/j. humpath.2012.11.006. DOI: 10.1016/j.humpath.2012.11.006
Wang Y., Li J., Xia Y., et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy // J. Clin. Oncol. - 2013. - Vol. 31(9). - P. 11881195. - DOI: 10.1200/JCO.2012.41.5984
West J., Wood H., Logan R.F., et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001// Br. J. Cancer. - 2006. - Vo. 94(11). - P. 1751-1758.
Yamashita Y., Taketomi A., Itoh S., et al. Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers // Jpn J. Clin. Oncol. - 2010. - Vol. 40(1). -P. 24-28. - DOI: 10.1093/jjco/hyp119
Yang H., Zhou J., Wei X., et al. Survival outcomes and progonostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: Adjuvant therapy is a favorable prognostic factor // Mol. Clin. Oncol. - 2014. - Vol. 2(6). - P. 1069-1075. - 10.3892/ mco.2014.377. DOI: 10.3892/mco.2014.377
Yang X., Wang W., Wang C., et al. Characterization of EGFR family gene aberrations in cholangiocarcinoma // Oncol Rep. - 2014. - Vol. 32(2). - P. 700-708. - DOI: 10.3892/or.2014.3261
Yi J.H., Thongprasert S., Lee J., et al. A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study // Eur. J. Cancer. - 2012. - Vol. 48(2). - P. 196-201. - DOI: 10.1016/j.ejca.2011.11.017
Yoshikawa D., Ojima H., Iwasaki M., et al. Clinicopatho-logical and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma // Br. J. Cancer. - 2008. - Vol. 98 (2). - P. 418-425. - DOI: 10.1038/sj.bjc.6604129
Yusuf M.A., Kapoor V.K., Kamel R.R., et al. Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Middle East and North Africa region // J. Natl. Compr. Canc. Netw. - 2010. - Vol. 8 (Suppl 3). - P. S36-40.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018